Evidence map›Paper›PMID 19077230›Full record

ArticleBMC psychiatry2008

Investigation of G72 (DAOA) expression in the human brain.

Isabel Benzel, James N C Kew, Ramya Viknaraja, Fiona Kelly, Jacqueline de Belleroche, Steven Hirsch, Thirza H Sanderson, Peter R Maycox

Open access · goldAbstract read
In one paragraph

Article in BMC psychiatry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 33 citations in OpenAlex.

  1. The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Trial
  2. Review
  3. Review
  4. Review
  5. D-Amino Acid Oxidase-pLG72 Interaction and D-Serine Modulation.Frontiers in molecular biosciences · 2018
    Review
  6. Expression of D-Amino Acid Oxidase (Frontiers in neuroanatomy · 2017
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. The C-terminal region of G72 increases D-amino acid oxidase activity.International journal of molecular sciences · 2013
    Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Isabel BenzelPsychiatry, GlaxoSmithKline, New Frontiers Science Park, Harlow, Essex, CM19 5AW, UK. isabel.benzel@gmx.net
James N C Kew
Ramya Viknaraja
Fiona Kelly
Jacqueline de Belleroche
Steven Hirsch
Thirza H Sanderson
Peter R Maycox
GlaxoSmithKline (United Kingdom) · GBImperial College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolymorphisms at the G72/G30 locus on chromosome 13q have been associated with schizophrenia or bipolar disorder in more than ten independent studies. Even though the genetic findings are very robust, the physiological role of the predicted G72 protein has thus far not been resolved. Initial reports suggested G72 as an activator of D-amino acid oxidase (DAO), supporting the glutamate dysfunction hypothesis of schizophrenia. However, these findings have subsequently not been reproduced and reports of endogenous human G72 mRNA and protein expression are extremely limited. In order to better understand the function of this putative schizophrenia susceptibility gene, we attempted to demonstrate G72 mRNA and protein expression in relevant human brain regions.

methodsThe expression of G72 mRNA was studied by northern blotting and semi-quantitative SYBR-Green and Taqman RT-PCR. Protein expression in human tissue lysates was investigated by western blotting using two custom-made specific anti-G72 peptide antibodies. An in-depth in silico analysis of the G72/G30 locus was performed in order to try and identify motifs or regulatory elements that provide insight to G72 mRNA expression and transcript stability.

resultsDespite using highly sensitive techniques, we failed to identify significant levels of G72 mRNA in a variety of human tissues (e.g. adult brain, amygdala, caudate nucleus, fetal brain, spinal cord and testis) human cell lines or schizophrenia/control post mortem BA10 samples. Furthermore, using western blotting in combination with sensitive detection methods, we were also unable to detect G72 protein in a number of human brain regions (including cerebellum and amygdala), spinal cord or testis. A detailed in silico analysis provides several lines of evidence that support the apparent low or absent expression of G72.

conclusionOur results suggest that native G72 protein is not normally present in the tissues that we analysed in this study. We also conclude that the lack of demonstrable G72 expression in relevant brain regions does not support a role for G72 in modulation of DAO activity and the pathology of schizophrenia via a DAO-mediated mechanism. In silico analysis suggests that G72 is not robustly expressed and that the transcript is potentially labile. Further studies are required to understand the significance of the G72/30 locus to schizophrenia.

Indexed as

Bipolar DisorderBrainCarrier ProteinsCell LineChromosome MappingChromosomes, Human, Pair 13D-Amino-Acid OxidaseEnzyme ActivationGenetic Predisposition to DiseaseGlutamic AcidHumansIntracellular Signaling Peptides and ProteinsMolecular Probe TechniquesPolymorphism, GeneticPromoter Regions, GeneticProtein Interaction Domains and MotifsCarrier ProteinsD-Amino-Acid OxidaseDAOA protein, humanDAO protein, humanGlutamic AcidIntracellular Signaling Peptides and ProteinsRNA, Messenger

Identifiers

PMID19077230
PMCPMC2630984
OpenAlexW2053295419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.